Evidence mapPaperPMID 40843019Full record

ArticleJournal of ginseng research2025

Ginsenoside Rb1 attenuates coronary microvascular inflammatory injury via NDUFS4-SIRT5-DUSP1-mediated mitochondrial quality control in a murine ischemia-reperfusion model.

Xiangyi Pu, Jinfeng Liu, Yanli Wang, Xuanke Guan, Qiaomin Wu, Qin Zhang, Ruxiu Liu, Xing Chang

Abstract read
In one paragraph

Article in Journal of ginseng research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Ginsenosides fromJournal of ginseng research · 2026
    Review
  4. Article
  5. Journal of ginseng research · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiangyi PuGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Jinfeng LiuGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Yanli WangGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Xuanke GuanGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Qiaomin WuGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Qin ZhangGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Ruxiu LiuGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Xing ChangGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ginsenoside Rb1 is a prominent bioactive component in traditional Chinese medicine. Purpose: This study investigated the molecular mechanisms underlying the protective effects of Ginsenoside Rb1 on endothelium during ischemia-reperfusion (I/R) injury. Materials and methods: To enrich for marker genes and investigate the differential expression of DUSP1 and NDUFS4 in coronary artery disease, single-cell transcriptome sequencing was utilized. SIRT5 Results: NDUFS4 and DUSP1 regulate the mitochondrial unfolded protein response (mtUPR), energy metabolism, and dynamics, and may be crucial regulatory genes in the development of coronary artery disease. Ginsenoside Rb1 modulates the NDUFS4-SIRT5-DUSP1 axis, regulates the mitochondrial quality control network, and alleviates coronary microvascular inflammatory injury. Conclusions: Ginsenoside Rb1 regulates the NDUFS4-SIRT5-DUSP1 axis, modulating the mitochondrial quality control network, inhibiting the inflammatory cascade response, and improved myocardial function.

Indexed as

DUSP-1InflammationMitochondrial quality controlNDUFS-4SIRT5

Identifiers

PMID40843019
PMCPMC12365519

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.